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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) and neu-
rofibromatosis type 1 (NF1) are both autosomal dominant disorders with a high rate 
of novel mutations. However, the two disorders have distinct and well-delineated ge-
netic, biochemical, and clinical findings. Only a few cases of coexistence of ADPKD 
and NF1 in a single individual have been reported, but the possible implications of 
this association are unknown.
Methods: We report an ADPKD male belonging to a family of several affected 
members in three generations associated with NF1 and optic pathway gliomas. The 
clinical diagnosis of ADPKD and NF1 was performed by several image techniques.
Results: Linkage analysis of ADPKD family was consistent to the PKD2 locus by 
a nonsense mutation, yielding a truncated polycystin-2 by means of next-generation 
sequencing. The diagnosis of NF1 was confirmed by mutational analysis of this gene 
showing a 4-bp deletion, resulting in a truncated neurofibromin, as well. The impact 
of this association was investigated by analyzing putative genetic interactions and 
by comparing the evolution of renal size and function in the proband with his older 
brother with ADPKD without NF1 and with ADPKD cohorts.
Conclusion: Despite the presence of both conditions there was not additive effect of NF1 
and PKD2 in terms of the severity of tumor development and/or ADPKD progression.
K E Y W O R D S
autosomal dominant polycystic kidney disease (ADPKD), neurofibromatosis type 1 (NF1),  
next-generation sequencing (NGS), NF1 mutation, optic pathway gliomas, PKD2
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1 |  INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) and 
neurofibromatosis type 1 (NF1) (MIM#: 162200) are both inher-
ited as autosomal dominant disorders (Bergmann et al., 2018; 
Stewart, Korf, Nathanson, Stevenson, & Yohay, 2018; Torres, 
Harris, & Pirson, 2007; Ward & Gutmann, 2005). ADPKD is 
the most common hereditary kidney disease, resulting from 
mutations in PKD1 (MIM#: 601313) and PKD2 (MIM#: 
173910) genes, located in chromosomes 16p13.3 (in approx-
imately 85% of cases) and 4q22.1 (in approximately 15% of 
cases), respectively. A rarer and newly discovered third locus 
including GANAB (MIM#: 104160) gene (at 11q12.3); is also 
associated with autosomal dominant polycystic liver disease 
in <1% of cases (Besse et al., 2018). In ADPKD, the growth 
of renal cysts produces a progressive increase in renal volume 
and destruction of the parenchyma, resulting in renal failure 
in the majority of affected individuals. However, disease pro-
gression of ADPKD is highly variable, in part because of a 
strong gene locus effect (Audrézet et  al.,  2016; Magistroni 
et al., 2003; Rossetti et al., 2002; Stewart et al., 2018), or by a 
possible modifier effect as it is suggested by a significant in-
tra-familial renal disease variability (Harris & Rossetti, 2010). 
Polycystin-1 and polycystin-2, the proteins encode by PKD1 
and PKD2 genes, respectively, are involved in many func-
tions of cell proliferation through the cellular GTPase systems 
(Delmas et al., 2002; Gogusev et al., 2003; Kim et al., 1999). 
NF1 is also relatively common and is caused by a mutation in 
the NF1 gene (MIM#: 613113), which is present on chromo-
some 17q11.2 (Abramowicz & Gos, 2014; Hirbe & Gutmann, 
2014; Ward & Gutmann,  2005). This gene codes for a pro-
tein known as neurofibromin, which is involved in inhibiting 
the cell proliferation (Abramowicz & Gos,  2014; Hirbe & 
Gutmann, 2014; Ward & Gutmann, 2005). Both diseases are 
known to co-exist with a number of other hereditary diseases, 
such as tuberous sclerosis, Von Hippel-Lindau, Marfan dis-
ease, Noonan syndrome, hereditary breast cancer, pheochro-
mocytoma, or multiple endocrine neoplasia type 2 (Alaraj 
et al.., 2007; Campos et al., 2013; Chatha et al., 2001; Erbay, 
Oljeski, & Bhadelia,  2004; Ercolino et  al.,  2014; Hateboer, 
Buchalter, Davies, Lazarou, & Ravine,  2000; Martignoni 
et al., 2002; Oktenli, Gul, & Deveci, 2004; Prada et al., 2011; 
Sampson et al., 1997; Syro et  al.,  2012; Thiel et  al.,  2009; 
Wheeler & Sadeghi-Nejad,  2005). However, co-occurrence 
of these two diseases (ADPKD and NF1) in a single individ-
ual is extremely rare. To the best of our knowledge, only a 
few cases have been reported in the literature (Table 1; Chen, 
Chen, Hou, Lee, & Huang, 2002; Flego et al., 2003; Niemczyk 
et al., 2010; Siegelman, Zavod, & Hecht, 1971; Varma, Talwar, 
Kushik, & Sharma, 1982). In only one of these cases, there 
was inheritance of one condition, ADPKD, and sporadic case 
and de novo mutation of the other, at NF1, was assumed (Chen 
et al., 2002). However, an association of NF1 with optic path-
way gliomas and ADPKD confirmed by molecular genetic 
analysis of the two genes has not been previously described.
Herein, we report a case of an ADPKD family, in which 
co-occurrence of pathogenic PKD2 and NF1 mutations in 
a single individual has been revealed based on clinical and 
genetic studies. We characterize the genetic background in 
the proband and his family members and discuss the putative 
genotype-phenotype correlations. Due to the influence that 
may have each disorder on the other, we also analyse possible 
implications of the presence of PKD2 and NF1 in the same 
individual and the possibility that this might have resulted 
in putative genetic interactions and/or additive or synergistic 
effects through biochemical pathways. Finally, we compared 
the clinical evolution of this rare case with his older brother 
with isolated ADPKD and with others control ADPKD pop-
ulations followed up by our center. To our knowledge, this is 
the first reported case of NF1 associated with ADPKD sub-
jected to clinical and extensive molecular studies.
2 |  MATERIALS AND METHODS
2.1 | Case presentation
A 17-year-old male with maternal familial history of 
ADPKD visited our outpatient clinic for renal evaluation in 






history NF1 Age, years Sex
Siegelman 1971 1 No Yes 54 M
Varma 1982 1 No No 40 F
Chen 2002 3 Yes Yes 47, 18, 17 F, M, M
Flego 2003 1 Yes Yes 50 M
Current report 2019 1 Yes No 30 M
Abbreviations: ADPKD, Autosomal dominant polycystic kidney disease; N, number of patients; NF1, 
neurofibromatosis type 1.
T A B L E  1  List of published series of 
patients with concurrence of ADPKD and 
NF1
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His past medical history was significant for NF1, diagnosed 
(using NIH consensus criteria) (NIH, 1988) in infancy by 
the presence of several café-au-lait spots in different part 
of his body, as well as axillary and inguinal frecklings. The 
patient also had optic pathway gliomas since age 5, which 
was documented by magnetic resonance imaging (MRI) se-
rial studies. Visual field testing and visually evoked poten-
tials were also confirmatory. In addition, an ophthalmologic 
examination at age of 16  years old revealed a decrease of 
visual field. Physical examination at the time of renal evalu-
ation revealed a normal blood pressure and the presence of 
multiple café-au-lait spots over trunk, neck, and extremities 
(Figure 1a). Axillary and inguinal frecklings were also found. 
He had a serum creatinine of 0.75 mg/dl and estimated glo-
merular filtration rate (eGFR) of 111  ml/min/1.73  m2. An 
ultrasonography (US), a computed tomography (CT), and a 
MRI of the abdomen showed both kidneys with several cysts 
of variable size. A cranial MRI demonstrated optic pathway 
gliomas involving the optic nerves and chiasm (Figure 1b). 
There were focal areas of increased signal intensity on T2 
in the bilateral globus pallidus, hippocampus, amygdala, cer-
ebellar hemispheres, and periventricular white matter. It was 
considered that he did not require specific treatment. Because 
the familial history of cerebral hemorrhage, MRI angiogra-
phy screening for intracranial aneurysms was performed at 
age of 17 and 20  years, respectively, yielding both nega-
tive results. At age of 22 years old he had a serum cystatin 
C 0.68  mg/dl and estimated glomerular filtration rate (eG-
FRCysC) of 141 ml/min/1.73 m
2. Total kidney volume (TKV) 
and height adjusted total kidney volume (htTKV) determined 
by MRI were measured by manual segmentation (Bae, 
Commean, & Lee, 2000). The patient had a TKV of 521 ml 
and an htTKV of 320 ml/m, and 6 years later (at age of 28) 
the TKV was 587 ml and htTKV 360 ml/m (Figure 1c) (an 
annual increase of 2.1%). Currently, he has a normal blood 
pressure, a serum cystatin C of 0.69 mg/dl and eGFRCysC of 
111  ml/min/1.73  m2 (Table  2). There was no clinical evi-
dence of the presence of cutaneous neurofibromas, plexiform 
F I G U R E  1  Clinical features for concurrence of NF1 and ADPKD in the proband. (a) Presence of café-au-lait spots over neck, trunk, and 
extremities. (b) Axial MRI at the age of 17 years showing bilateral thickening of the optic nerve and chiasm. There were focal areas of increased 
signal intensity on T2 in the bilateral globus pallidus and hippocampus. (c) Coronal T2-weighted MRI scan of the abdomen in the proband at the 
age of 28 years showing a TKV of 587 ml (htTKV of 360 ml/m). (d) Coronal T2-weighted MRI scan of the abdomen in his brother at the age of 
30 years showing a TKV of 791 ml (htTKV of 437 ml/m). ADPKD, Autosomal dominant polycystic kidney disease; htTKV, height adjusted total 
kidney volume; MRI, magnetic resonance imaging; NF1, neurofibromatosis type 1; TKV, total kidney volume
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neurofibromas, pheochromocytomas or other tumor types. In 
this way, he had negative results in serial abdominal and pel-
vic US, CT, and MRI.
2.2 | Family history
There was no family history of NF1, but the family history 
was positive for ADPKD. All available members of the fam-
ily were screened at least once by abdominal US, CT, or MRI 
and the diagnosis of ADPKD was confirmed according to 
recognized criteria (Pei et  al.,  2009). Reviewing the fam-
ily history, maternal grandmother, mother, maternal aunt, 
and older brother of the proband were affected by ADPKD. 
His maternal grandmother presented end stage renal disease 
(ESRD) from ADPKD at age of 70 years and deceased from 
a cerebral hemorrhage at the age of 71 years. His maternal 
aunt was found to have also ADPKD at 37 years of age and 
presented ESRD at age of 60. His mother was found to have 
ADPKD at 35 years of age and presented ESRD at age of 
49. His older brother was found to have bilaterally enlarged 
kidneys with several cysts (6–8) of variable size at age of 
14 years. At age of 24 he has a serum cystatin C of 0.65 mg/dl 
and eGFRCysC of 149 ml/min/1.73 m
2; TKV was 634 ml and 
HtTKV 350 ml/m, and 6 years later (at age of 30) the TKV 
was 791  ml and HtTKV 437  ml/m (Figure  1d) (an annual 
increase of 4.2%). Currently, he has a normal blood pressure, 
a serum cystatin C of 0.79 mg/dl and eGFRCysC of 118 ml/
min/1.73 m2 (Table 2). His younger brother currently with 
28 years of age showed no evidence of ADPKD so far. MRI 
angiography screening for intracranial aneurysms of all fam-
ily members with ADPKD was negative.
2.3 | Follow-up study
To document the evolution of ADPKD, MRI, and eGFR se-
rial studies in both brothers and three control ADPKD co-
horts (among the patients with ADPKD followed up by our 
center) were performed. To this end, TKV and htTKV were 
also determined in these ADPKD cohorts. The eGFR was 
determined using the serum creatinine and the serum cystatin 
C values. Cystatin C level was used to calculate eGFR using 
the formula: eGFRCysC = 77.24 × (Cys
−1.2623). Mayo clinic 
imaging classification and the prediction of future eGFR 
based on the classification were determined in both brothers 
(Irazabal et al., 2015). In addition, we compared the clinical 
evolution of the proband with his older brother with ADPKD 
only and with three control ADPKD defined cohorts: (PKD2 
patients, N = 12), (ADPKD without hypertension, N = 23) 
and (ADPKD ≤ 40 years, N = 58) (Table 2).
2.4 | Molecular genetics
2.4.1 | ADPKD by microsatellite analysis
We initially ascertained the complete pedigree of the family 
over three generations and clinically assessed and genotyped 
all available members with polymorphic markers at PKD1 
and PKD2 locus. Haplotype analysis by microsatellite mark-
ers KG8 (intragenic) and OT2 (D16S521) for PKD1 and 
D4S1534, JV106, D4S1563, and D4S423 for PKD2 were 
done (Coto et al., 1995).
2.4.2 | ADPKD by multiplex ligation-
dependent probe amplification analysis
Autosomal dominant polycystic kidney disease gross deletion 
analysis were made by means of multiplex ligation-dependent 
probe amplification (MLPA) using the SALSA MLPA KIT 
P351/P352 for PKD1/PKD2 (MRC-Holland), following 
manufacturer´s instructions. Data analysis were done with 
Coffalyser v6 MLPA Analysis Software (MRC-Holland).
2.4.3 | ADPKD massive parallel 
sequencing analysis
The use of massive parallel sequencing technologies for in-
depth analysis of large numbers of genes simultaneously is 




ADPKD patients without HT 
(N = 23, mean ± SD)
ADPKD patients ≤ 40 years old 
(N = 58, mean ± SD)
Age, years 28 30 38 ± 6.4 35 ± 5.6 33.1 ± 6.3
TKV, ml 587 791 727 ± 359 662 ± 223 1,301 ± 966
HtTKV, ml/m 360 437 428 ± 205 382 ± 124 752 ± 563
Annual TKV, % 2.1 4.2 5.5 ± 2.3 5.6 ± 4.4 7.3 ± 5.3
eGFRCysC, ml/
min/1.73 m2
111 118 112 ± 13 137 ± 19 119 ± 30
Abbreviations: ADPKD, Autosomal dominant polycystic kidney disease; HT, hypertension; HtTKV, height adjusted total kidney volume; TKV, total kidney volume.
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a time-efficient and a cost-effective manner, and the advan-
tages of its use in diagnostic screening of human diseases, 
including renal diseases, have recently been demonstrated 
(Harris,  2018). We used a custom-targeted next-generation 
sequencing (NGS) gene panel (NEFROseq v1.1) for the 
study of the full spectrum of genetic nephropathies (which 
includes 250 genes implicated in etiology of kidney dis-
eases). The sequence was captured using SeqCap EZ tech-
nology (Roche Nimblegen) and subsequently sequenced 
on a NextSeq500 (Illumina). Bioinformatics analysis was 
performed in the house Bioinformatics’ core using publicly 
available software tools (trimmomatic-0.32; Bowtie2 v2.1.0; 
Picard-tools v1.27; Samtools v0.1.19-44428cd; Bedtools 
v2.26.0; Genome Analysis TK v3.3-0 y SnpE 4.1l; ClinVar 
date 20140703 dbscSNV1.1 dbNSFP version 3.0 dbSNP 
v138), and simultaneously with variant Caller V2.1 tool 
(Illumina). In silico pathogenicity prediction was analyzed 
using Alamut 2.7 (interactive Biosoftware) and others such 
as SIFT ensembl 66; Polyphen-2 v2.2.2; Mutation Assessor, 
release 2; FATHMM, v2.3; Gerp2; PhyloP; CADD, v1.3. 
Population frequencies of the detected variants were assessed 
using the Exome Aggregation Consortium (ExAC; Exac 
r0.3) data (http://exac.broad insti tute.org); 1000 genome pro-
ject; Spanish Exon Variant Project; NHLBI exome sequenc-
ing project: ESP6500_EA_AF; Candidate variants in the 
proband were subsequently confirmed by Sanger sequencing, 
as was family testing.
2.4.4 | Sanger sequencing
PKD2 mutation screening for coding sequences and intron/
exon boundaries for exon 8 (PKD2; NM_000297.3) was per-
formed by direct sequencing. PCR conditions and Primers 
(designed with the help of Primer3 plus v04.0 Software) 
were available upon request. PCR products were sequenced 
using BrightDye Terminator cycle kit (Nimagen) and run on 
a ABI3730XL Sequencer (Thermo Fisher).
2.4.5 | Complete NF1 mutational analysis
Comprehensive NF1 gene mutation screen involved MLPA 
analysis and mRNA-based mutation detection by RT-PCR 
and denaturing high-performance liquid chromatography 
(DHPLC) (Valero et al., 2011; Valero, Velasco, Moreno, & 
Hernández-Chico, 1994). Genomic DNA was purified from 
peripheral blood leucocytes by standard procedure and RNA 
was extracted using QIAamp® RNA Blood kit (QIAGEN). 
Screening for NF1 single and multi-exon deletions was per-
formed using the SALSA MLPA KIT P081/P082 NF1 (MRC-
Holland), as instructed by the manufacturer. Data analysis 
were done with Coffalyser v6 MLPA Analysis Software 
(MRC-Holland). RNA was reverse transcribed using First 
Strand cDNA Synthesis Kit for RT-PCR (AMV) and random 
hexamers (Roche). The entire coding region of NF1 gene was 
amplified in 23 overlapping fragments and DHPLC was per-
formed on a WAVE DNA fragment analysis system using 
a DNAsep column (Transgenomic). Variant profiles were 
characterized by sequencing the product of a second PCR 
amplification using an ABI PRISM 3100 Genetic Analyser 
(Applied Biosystems). Mutation identified was confirmed in 
genomic DNA by direct sequencing. Mutation and its puta-
tive effect at the protein level have been named according 
to the Human Genome Variation Society guidelines (den 
Dunnen & Antonarakis, 2003). Mutation numbering is based 
on the NF1 mRNA sequence from Genbank (NM_000267.2), 
with the A of the translation start codon considered as nu-
cleotide number 1. Exons are not named consecutively but 
according to the accepted nomenclature used by researchers 
in the field.
3 |  RESULTS
3.1 | ADPKD family
The pedigree of the family is plotted in Figure 2. Tracing 
the family history of the proband (III-2), several members, 
including his mother (II-1), maternal grandmother (I-1), 
and maternal aunt (II-3) were all affected by ADPKD. His 
older brother (III-1) was found to have also ADPKD at the 
age of 14 years. Consistent with linkage results, ADPKD 
affected brother and other affected family members do not 
share the same PKD1 maternal haplotype. This result may 
it initially focused in PKD2 gene. In fact, from the four 
microsatellite markers used for PKD2, one of them (JV106, 
next to the gene) was shared with the affected brother, and 
not with definitively unaffected members of this family 
(data not shown). The rest of microsatellites resulted non-
informative. This weak haplotype segregation implied later 
the use of our NGS custom designed targeted panel for in-
herited nephropathies (Nefroseq v1.1). We detected in our 
proband a previously described nonsense heterozygous 
PKD2 mutation NM_000297.3:c.2407C>T; p.Arg803Ter 
(Figure 3a) in exon 13, resulted in a truncated polycystin 
2 protein, that was definitely pathogenic (Mayo’s Clinic 
ADPKD mutation database; http://pkdb.mayo.edu/ and 
LOVD, HGMD, Clin Var) and reported in different eth-
nicity (Audrezetet al.,  2012; Choi et  al.,  2014; Chung 
et  al.,  2006; Deltas,  2001; Zhang et  al.,  2005). This mu-
tation changed the Arg417 codon, CGA, to a stop codon, 
TGA, resulting in a predicted truncated protein 803 amino 
acids shorter than normal (Zhang et  al.,  2005). ACMG/
AMP classification was pathogenic (PVS1, PM2, PP3, 
PP4, PP5), with several in silico predictors as damaging 
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(DANN, CADD, Mutation Taster, FATHMM-MKL, LRT, 
EIGEN, EIGEN PC) and highly conserved (GERP). The 
variant was not previously observed in European non-
Finnish (genomAD; Exomes and Genomes). This patho-
genic variant was validated by Sanger sequencing, as well 
as other available affected family members (the proband`s 
mother, proband`s aunt, and proband`s older brother).
3.2 | NF1 genetic
Moreover, the proband (III-2) presented café-au-lait spots at 
birth, which increased in number and size in the first years of 
life associated to axillary and inguinal freckling. He was later 
found to have optic gliomas, confirming the presence of NF1. 
There was no family history of NF1 and his two brothers 
have no stigmata at all of neurofibromatosis, suggesting that 
a de novo NF1 mutation occurred in the proband. Mutational 
analysis of NF1 gene found a 4-bp deletion NM_0010424
92.3:c.1756_1759delACTA; p.Thr586ValfsTer18 at exon 
12a, yielding a putative truncated neurofibromin (Figure 3b). 
The variant has been previously described in different eth-
nic groups (Ars et al., 2003; Nemethova et al., 2013; Park & 
Pivnick, 1998; Pemov et al., 2017; Yap et al., 2017). ACMG/
AMP classifies this change as pathogenic (PVS1, PM2, PP3, 
PP4, PP5). Population frequencies is low in European non-
Finnish (1/311502). This mutation was detected neither in his 
parents nor in his brothers.
Therefore, the coexistence of these two disorders in this 
male may be simply the coincidental inheritance of the ma-
ternal PKD2 gene mutation (at chromosome 4q22.1) and de 
novo mutated NF1 gene in chromosome 17q11.2 band, which 
seemed to be associated with optic gliomas formation.
3.3 | ADPKD progression
Our proband (III-2) showed that his kidney size (htTKV) 
does not differ significantly from his older brother with 
ADPKD only (III-1) and from two ADPKD cohorts: (PKD2 
patients) and (ADPKD without hypertension) (Table  2). 
However, the annual rate of htTKV growth in the proband 
was approximately 50% when compared with his older 
brother and with these two ADPKD cohorts. In addition, in 
both brothers and two control ADPKD cohorts, (PKD2 pa-
tients) and (ADPKD without hypertension) the htTKV and 
the annual rate of htTKV growth were smaller than in other 
cohort (ADPKD ≤ 40 years). Moreover, in both brothers the 
F I G U R E  2  Pedigree of the family with PKD2 and NF1. The number is the year of birth. The arrow shows the proband. NF1, 
neurofibromatosis type 1
   | 7 of 13PECES Et al.
eGFRCysC was not different that in our three control ADPKD 
cohorts. Moreover, both brothers were classified as 1C class 
(moderate risk of progression) and the prediction of future 
eGFR based on Mayo imaging classification was superim-
posable in both (ESRD at 64 and 63 years, respectively).
4 |  DISCUSSION
4.1 | NF1 and genotype-phenotype 
correlations
The principal clinical features of NF1 disease are café-au-lait 
spots, neurofibromas, Lisch nodules (hamartomas) of the iris, 
axillary/inguinal freckling and optic gliomas. It is character-
ized by a highly variable expressivity and age-dependent clin-
ical features, including vascular abnormalities that are also 
a recognized characteristic of neurofibromatosis (Alkindy, 
Chuzhanova, Kini, Cooper, & Upadhyaya,  2012; Bargiela 
et al., 2018; Hitchcock & Gibson, 2017; Kebudiet al., 2008; 
Kurtelius et al., 2017; Rasmussen, Yang, & Friedman, 2001; 
Stewart et  al.,  2018; Sylvester, Drohan, & Sergott,  2006). 
Thus, NF1 patients under 29 years of age have an increased 
prevalence of intracranial aneurysms relative to the general 
population risk (Hitchcock & Gibson, 2017). On the other 
hand, the incidence of pheochromocytoma in NF1 is esti-
mated between 0.1% and 5.7%, where 22% are asymptomatic. 
In autopsy series the incidence is higher, between 3% and 
13%, and the median age of pheochromocytoma presenta-
tion in one previous study was 43 years (Gorgel et al., 2014; 
Walther, Herring, Enquist, Keiser, & Linehan,  1999). 
Furthermore, just about half of people with NF1 do not have 
plexiform neurofibromas, but most are internal and not sus-
pected clinically (Mautner et al., 2008; Plotkin et al., 2012; 
Tonsgard, Kwak, Short, & Dachman,  1998) and also most 
of these tumors grow slowly. When symptomatic, plexiform 
neurofibromas can cause disfigurement and may compro-
mise function affecting quality of life.
The NF1 gene codes for a protein known as neurofibro-
min, which is expressed in many tissues, including brain, 
kidney, spleen, and thymus and is involved in inhibiting cell 
proliferation. Among its many roles, the most important 
function can be the tumor suppression through the cellu-
lar GTPase systems (Abramowicz & Gos,  2014; Hirbe & 
Gutmann, 2014; Ward & Gutmann,  2005). In fact, muta-
tions in the NF1 gene result in loss of functional protein, 
causing the wide spectrum of clinical findings including 
NF1-associatedtumors. Interestingly, only approximately 
15%–20% of patients with NF1 develop optic glioma, some-
times as the first sign of subtle NF1 (Kebudiet al., 2008) and 
10% of these children will have tumor progression (Sylvester 
et  al.,  2006). Approximately one-half of the cases of NF1 
are familial; the remainder are sporadic cases, due to de 
novo mutations in NF1 gene (Ward & Gutmann, 2005). A 
F I G U R E  3  Molecular establishment of both mutations in the proband. (a) NGS PKD2 view of the nonsense mutation at the exon 13; 
(c.2407C>T; p.Arg803Ter). (b) Sanger sequencing of mutated NF1 allele; (c.1756delACTA; p.Thr586ValfsTer18) at exon 12a, yielding a putative 
truncated neurofibromin. NF1, neurofibromatosis type 1; NGS, next-generation sequencing
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360–amino acid region of the gene product shows homol-
ogy to the catalytic domain of the mammalian GTPase-
activating proteins (GAP). This region is referred to as the 
NF1-GAP–related domain (NF1 GRD) and is encoded by the 
central portion of the NF1 gene, which encompasses exons 
21–27a. The GAP proteins downregulate the activity of the 
RAS oncogene by stimulating its intrinsic GTPase activity 
that converts the active, guanine triphosphate (GTP)-bound 
form of p21 Ras to the inactive guanine diphosphate–bound 
form in the very early stages of the signal transduction 
cascade. Among the numerous NF1 mutations reported to 
date, very few of them correlate with the NF1 tumor phe-
notype (Alkindy et  al.,  2012). Functional studies showed 
that NF1-GRD mutations reduced the GAP activity from 
200- to 400-fold, but no relationship has been demonstrated 
with the NF1 phenotype (Deltas, 2001). In fact, the frame-
shift mutation deletion in exon 12a, c.1756_1759delACTA, 
found in our proband seemed to be associated with the optic 
glioma observed at early age. As our patient, other patients 
with optic gliomas had the same mutation; c.1756_1759de-
lACTA (Park & Pivnick, 1998; Rasmussen et  al.,  2001), 
which is outside the GRD. In addition, in one of previous 
studies, all patients with optic glioma harbor mutations 
yielding truncated neurofibromins (Park & Pivnick, 1998). 
However, c.1756_1759delACTA mutation does not neces-
sarily correlate with tumor phenotype. Moreover, absence 
of mutations in the GRD region in other patients who devel-
oped tumors indicates that other regions of neurofibromin 
are probably also involved in modulating ras GTPase activ-
ity. Indeed, modifying genes may be involved in the variabil-
ity of NF1 expression. This is supported by the observation 
that identical NF1 specific mutations do not cause the 
same phenotypes in unrelated NF1 patients. Furthermore, 
our patient did not have plexiform neurofibromas, whereas 
other patients wearing the same change (c.1756_1759de-
lACTA), describe the presence of these (Ars et  al.,  2003; 
Park & Pivnick, 1998). In addition, our patient was under 
30´s, had normal blood pressure and different image test-
ing did not show any trace of pheochromocytoma (Gorgel 
et  al., 2014; Walther et  al., 1999). Finally, to be remarked 
that regarding these genotype-phenotype correlation-ships 
is that our patient currently, had mild-moderate phenotype 
of NF1-disease with no plexiform neurofibromas, neither 
pheochromocytomas nor other tumor-associated complica-
tions, and stable and controlled optic gliomas. No specific 
phenotype can be associated to this variant observed in our 
subject. At this point only NF1 microdeletion patients pres-
ent a more severe phenotype than that observed in classi-
cal NF1 patients, particularly in respect to the presence of 
early appearance of cutaneous neurofibromas, more frequent 
and more severe learning disabilities, somatic overgrowth, 
and dysmorphic facial features, among others (Koczkowska 
et al., 2020; Messiaen et al., 2011; Pasmant et al., 2010).
4.2 | ADPKD progression
The hallmark characteristic of ADPKD is the progressive de-
velopment and expansion of cysts in the kidney leading to 
ESRD. It contributes to approximately 10% of ESRD patients 
in Europe (Cornec-Le Gall et al., 2017; Willey et al., 2017). In 
addition, it can be associated with several extrarenal manifes-
tations including hypertension, symptomatic extrarenal cysts, 
and subarachnoid hemorrhage from intracranial aneurysms 
(Audrézet et al., 2016; Hitchcock & Gibson, 2017; Magistroni 
et al., 2003; Rossetti et al., 2002). The vast majority of the pa-
tients develop the disease between the ages of 20–40 years, 
but, notably, among a small proportion (2%–5%) of ADPKD 
patient symptoms can manifest during childhood or even pre-
natally (“early onset,” before 15 years old) or even in utero 
(“very early onset”) (Audrézet et al., 2016). Moreover, there 
is evidence of genotype-phenotype correlation in ADPKD. 
Mutations in PKD1 cause more severe disease than PKD2, 
with ESRD occurring approximately 20 years earlier, at an 
average age of 58 years versus. 79 years. In addition, carriers 
of truncating mutations in PKD1 reach ESRD approximately 
12  years prior to those with missense mutations (Harris & 
Rossetti, 2010). Therefore, disease progression of ADPKD 
is highly variable, in part because of a strong gene locus ef-
fect (Rossetti et al., 2002; Magistroni et al., 2003; Audrézet 
et al., 2016; Harris & Rossetti, 2010) or by a modifier effect, 
as it has been suggested by a significant intrafamilial renal 
disease variability in ADPKD (Cornec-Le Gall et al., 2017; 
Cornec-Le Gall et al., 2018).
4.3 | Co-occurrence of ADPKD and NF1
A single individual carrying mutations in two different genes 
causing two different diseases, and, therefore, suffering both 
entities, is not common but depends on the prevalence of each 
disease. Because the prevalence of ADPKD in the general 
population is 1 in 500–1,000 (Torres et al., 2007) (whereas 
PKD2 genetic prevalence is estimated at 2.31/10,000) (Choi 
et al., 2014) and the prevalence of NF1 is approximately 1 in 
3,000 (Ward & Gutmann, 2005), concurrence of both diseases 
(ADPKD and NF1) is predicted to occur in 1 in 1,500,000–
3,000,000 individuals; concurrence of PKD2 disease and 
NF1 disease is predicted to occur in 1/13,043,400. Therefore, 
occurrence of both, ADPKD and NF1, in a single individual 
is very rare. In fact, only six patients have been reported in 
the literature (Chen et al., 2002; Flego et al., 2003; Siegelman 
et al., 1971; Varma et al., 1982; Table 1). Chen et al. (2002) 
thought that the co-occurrence of these two disorders to-
gether, in three members of a family, was due a de novo mu-
tation in NF1 gene that occurred in the ADPKD mother who 
transmitted both diseases to her two sons. Flego et al. (2003) 
reported a patient who inherited NF1 and ADPKD from his 
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mother and father, respectively. However, in just one of these 
cases was assumed a sporadic mutation for NF1 gene and the 
inheritance of other condition, and in only two cases this as-
sociation was related with tumor formation, but none of them 
with optic gliomas. Therefore, all of these reports, as in our 
case, it may be an association by chance. However, although 
ADPKD and NF1 are due to alterations in two different and 
independent genes, we cannot rule out the possibility of a 
genetic or biochemical interaction and/or causal relationship 
between these two anomalies. In both, ADPKD and in NF1 
disease loss of heterozygosity are involved as the mecha-
nism responsible for disease expression. Although PKD2 
and NF1 genes are not apparently located closely at the ge-
nome, their functions at the cellular level are intimately re-
lated (see Figure 4). They both are involved in inhibiting cell 
proliferation and differentiation through the GTPase systems 
(Abramowicz & Gos,  2014; Delmas et  al.,  2002; Hirbe & 
Gutmann, 2014; Kim et al., 1999). In view of the similarity of 
the underlying biochemical abnormality in PKD2 and NF1, 
the presence of both conditions in a single individual might 
lead (under this hypothesis) to a more severe disease particu-
larly in terms of tumor progression. Therefore, this might 
have resulted in additive or synergistic effect of dysfunc-
tional tumor-suppressor genes in rapid progression of optic 
gliomas in this unusual patient (Abramowicz & Gos, 2014; 
Erbay et al., 2004; Hirbe & Gutmann, 2014). In addition, in 
both diseases has been reported an associated high risk of 
intracranial aneurysms (ADPKD, 4%–17%; NF1, 9%–11%) 
(Erbay et al., 2004) and in case of associated mutations of 
the neurofibromin and polycystin-2 proteins it is expected to 
have additive or synergistic intracranial aneurysms disease 
presentation and/or associated tumors progression. However, 
inferred by our clinic observations, he did not appear to be 
more severely affected than is typically reported with either 
condition alone and in fact, we did not detect any intracra-
nial aneurysms. Thus, the absence of a synergistic effect 
may be explained by the underlying molecular function of 
the neurofibromin and polycystin-2 proteins. Indeed, loss of 
neurofibromin function reduces control of Ras and aberrant 
activation of the mTOR pathway leading to increased cell 
growth (Johannessen et  al.,  2005, 2008). Loss of polycys-
tin-2 function leads to increased cAMP activity, and hyper-
activation of mTOR and S6K (Delmas et al., 2002; Gogusev 
et al., 2003; Kim et al., 1999). While neurofibromin and poly-
cystin-2 act to restrain cell growth, they appear to be acting in 
a separate way. Thus, unlike astrocytes, in which cAMP acts 
as an antimitogenic signal, cAMP is a mitogen for Schwann 
cells, and neurofibromin functions to antagonize, rather than 
stimulate, cAMP production (Figure  4). Therefore, as it is 
denoted in our patient individuals with both PKD2 and NF1 
mutations seemed not have a greater risk for tumor and/or 
cerebral aneurysm formation than expected with either con-
dition alone. However, more individuals will need to support 
this fact. Moreover, the evidence that mTOR deregulation 
participates in NF1-related tumorigenesis and the recent 
finding that mTOR and its downstream effector S6K play 
a critical role in the pathogenesis of ADPKD, support the 
possibility that rapamycin could represent a viable therapy 
for patients with this rare association (Hegedus et al., 2008; 
Johannessen et  al.,  2005, 2008; Shillingford et  al.,  2006; 
Wahl et al., 2006; Wen & Kesari, 2008).
The case we present here has a de novo deletion in exon 12a 
of the NF1 gene and an inherited nonsense mutation in exon 
13 of the PKD2 gene. Although the functional consequences 
F I G U R E  4  Schematic view of cell growth and proliferation molecular pathways involved in neurofibromatosis type1 (NF1) (left) and 
autosomal dominant polycystic disease (ADPKD) (right) by GTPase signaling
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of NF1 mutation on ADPKD is not known, the absence of 
great differences on renal volume and renal function in the 
proband with respect to his older brother with ADPKD only 
and two ADPKD cohorts, is strongly suggestive of that NF1 
mutation do not have a pathogenic additive effect on ADPKD. 
In contrast, the difference in annual rate of htTKV growth be-
tween the proband and his older brother with ADPKD only 
and with two ADPKD cohorts may suggest a protective effect. 
Moreover, both brothers were classified as 1C class (moder-
ate risk of progression) and the prediction of future eGFR 
based on Mayo imaging classification was superimposable in 
both (ESRD at 64 and 63 years, respectively), which may be 
considered atypical for PKD2 (Cornec-Le Gall et al., 2017; 
Cornec-Le Gall et al., 2018). Interestingly, ADPKD in this 
family was originated by a truncating mutation in PKD2 and 
is a fact that the proband`s mother, proband`s aunt and pro-
band`s grandmother presented ESRD at age of 49, 60, and 
70, respectively, which may be considered as intra-familial 
renal disease variability for PKD2 and may suggest the pres-
ence of a modifier effect for rapid progression. So, ADPKD 
in this family was quite severe for PKD2 variant (Robinson 
et al., 2012), but what is most surprising is the apparent lim-
ited impact of an additional NF1 mutation in the proband.
5 |  CONCLUSION AND OUTLOOK
In summary, this is the first reported case of concurrence 
of a truncated NF1 mutation with optic pathway gliomas 
and a nonsense PKD2 mutation. Despite the presence of 
both conditions in a single individual, there was not addi-
tive or synergistic effect of dysfunctional tumor-suppressor 
genes in rapid formation of optic gliomas or in ADPKD 
progression in this unusual patient. In addition, the widely 
used of genomic approaches, such as NGS, may allowed 
us to find co-concurrence of more than one pathogenic 
variant in the patients, such as in our proband, which may 
mask an expected phenotype. Thus, we would like to alert 
to our colleagues the necessity of checking for more than 
one pathogenic variant in atypical phenotypes for known 
diseases.
ACKNOWLEDGMENTS
The authors thank the affected individual and their family 
who contributed to this study.
CONFLICTS OF INTEREST
The authors declare that there is no conflict of interest regard-
ing the publication of this paper.
DISCLOSURE
Dr. Peces was an investigator for an Oksuka-sponsered 
study investigating tolvaptan in the treatment of ADPKD 
(REPRISE). The other authors declare that they have not rel-
evant financial interests.
AUTHORS’ CONTRIBUTIONS
All authors were involved in drafting the manuscript, gave 
final approval for the version to be published and agreed to 
be accountable for all aspects of the work in ensuring that 
questions related to the accuracy or integrity of any part of 
the work are appropriately investigated and resolved. RP 
made substantial contributions to the concept/design and ac-
quisition, analysis, and interpretation of data. RM, YM, CH, 
CP, DT, EC, RS, PL, and JN made substantial contributions 
to the acquisition, analysis, and interpretation of data.
ETHICS APPROVAL AND CONSENT TO 
PARTICIPATE
This article was conducted in accordance with the World 
Medical Association Declaration of Helsinki, all its amend-
ments and national regulations.
CONSENT FOR PUBLICATION
Written informed consents were obtained from the patients 
for publication of this article.
DATA AVAILABILITY STATEMENT
The dataset supporting the conclusions of this article are in-
cluded within the article.
ORCID
Ramón Peces   https://orcid.org/0000-0002-9170-8746 
REFERENCES
Abramowicz, A., & Gos, M. (2014). Neurofibromin in neurofibro-
matosis type 1-mutations in NF1 gene as a cause of disease. 
Developmental Period Medicine, 18(3), 297–306.
Alaraj, A. M., Valyi-Nagy, T., Roitberg Bars, E., Kruyer, H., Morell, 
M., Pros, E., … Lázaro, C. (2007). Double phakomatosis; neuro-
fibromatosis type-1 and tuberous sclerosis. Acta Neurochirurgica, 
149(5), 505–509. https://doi.org/10.1007/s0070 1-007-1140-2
Alkindy, A., Chuzhanova, N., Kini, U., Cooper, D. N., & Upadhyaya, M. 
(2012). Genotype-phenotype associations in neurofibromatosis type 
1 (NF1): An increased risk of tumor complications in patients with 
NF1 splice-site mutations? Human Genomics, 6, 12.
Ars, E., Kruyer, H., Morell, M., Pros, E., Serra, E., Ravella, A., … 
Lázaro, C. (2003). Recurrent mutations in the NF1 gene are com-
mon among neurofibromatosis type 1 patients. Journal of Medical 
Genetics, 40, e82. https://doi.org/10.1136/jmg.40.6.e82
Audrézet, M. P., Corbiere, C., Lebbah, S., Morinière, V., Broux, F., 
Louillet, F., … Baudouin, V. (2016). Comprehensive PKD1 and 
PKD2 mutation analysis in prenatal autosomal dominant polycys-
tic kidney disease. Journal of the American Society of Nephrology, 
27(3), 722–729.
Audrezet, M. P., Cornec-Le Gall, E., Chen, J. M., Redon, S., Quere, I., 
Creff, J., … Ferec, C. (2012). Autosomal dominant polycystic kid-
ney disease: Comprehensive mutation analysis of PKD1 and PKD2 
   | 11 of 13PECES Et al.
in 700 unrelated patients. Human Mutation, 33(8), 1239–1250. 
https://doi.org/10.1002/humu.22103
Bae, K. T., Commean, P. K., & Lee, J. (2000). Volumetric measure-
ment of renal cysts and parenchyma using MRI: Phantoms and pa-
tients with polycystic kidney disease. Journal of Computer Assisted 
Tomography, 24(4), 614–619. https://doi.org/10.1097/00004 728-
20000 7000-00019
Bargiela, D., Verkerk, M. M., Wee, I., Welman, K., Ng, E., & Choong, A. 
M. T. L. (2018). The endovascular management of neurofibromato-
sis-associated aneurysms: A systematic review. European Journal of 
Radiology, 100, 66–75. https://doi.org/10.1016/j.ejrad.2017.12.014
Bergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, 
D. J. M., & Torres, V. E. (2018). Polycystic kidney disease. Nature 
Reviews Disease Primers, 4(1), 50. https://doi.org/10.1038/s4157 
2-018-0047-y
Besse, W., Choi, J., Ahram, D., Mane, S., Sanna-Cherchi, S., Torres, 
V., & Somlo, S. (2018). A noncoding variant in GANAB explains 
isolated polycystic liver disease (PCLD) in a large family. Human 
Mutation, 39(3), 378–382.
Campos, B., Balmaña, J., Gardenyes, J., Valenzuela, I., Abad, O., 
Fàbregas, P., … Díez, O. (2013). Germline mutations in NF1 and 
BRCA1 in a family with neurofibromatosis type 1 and early-onset 
breast cancer. Breast Cancer Research and Treatment, 139, 597–
602. https://doi.org/10.1007/s1054 9-013-2538-6
Chatha, R. K., Johnson, A. M., Rothberg, P. G., Townsend, R. R., 
Neumann, H. P., & Gabow, P. A. (2001). Von Hippel-Lindau disease 
masquerading as autosomal dominant polycystic kidney disease. 
American Journal of Kidney Diseases, 37(4), 852–858. https://doi.
org/10.1016/S0272 -6386(01)80136 -0
Chen, M.-H., Chen, K.-S., Hou, J.-W., Lee, C.-C., & Huang, J.-S. 
(2002). Coexistence of autosomal dominant polycystic kidney dis-
ease and neurofibromatosis: Report of a family. American Journal 
of Nephrology, 22(4), 376–380.
Choi, R., Park, H. C., Lee, K., Lee, M. G., Kim, J. W., Ki, C. S., … 
Ahn, C. (2014). Identification of novel PKD1 and PKD2 mutations 
in Korean patients with autosomal dominant polycystic kidney 
disease. BMC Medical Genetics, 15, 129. https://doi.org/10.1186/
s1288 1-014-0129-y
Chung, W., Kim, H., Hwang, Y. H., Kim, S. Y., Ko, A. R., Ro, H., … 
Ahn, C. (2006). PKD2 gene mutation analysis in Korean autoso-
mal dominant polycystic kidney disease patients using two-dimen-
sional gene scanning. Clinical Genetics, 70(6), 502–508. https://doi.
org/10.1111/j.1399-0004.2006.00721.x
Cornec-Le Gall, E., Audrézet, M.-P., Renaudineau, E., Hourmant, M., 
Charasse, C., Michez, E., … Le Meur, Y. (2017). PKD2-related au-
tosomal dominant polycystic kidney disease: Prevalence, clinical 
presentation, mutation spectrum, and prognosis. American Journal 
of Kidney Diseases, 70(4), 476–485. https://doi.org/10.1053/j.
ajkd.2017.01.046
Cornec-Le Gall, E., Chebib, F. T., Madsen, C. D., Senum, S. R., Heyer, 
C. M., Lanpher, B. C., …, Harris, P. C. (2018). The value of ge-
netic testing in polycystic kidney diseases illustrated by a family 
with PKD2 and COL4A1 mutations. American Journal of Kidney 
Diseases, 72(2), 302–308.
Coto, E., Sanz de Castro, S., Aguado, S., Alvarez, J., Arias, M., 
Menendez, M. J., & Lopez-Larrea, C. (1995). DNA microsatellite 
analysis of families with autosomal dominant polycystic kidney 
disease types 1 and 2: Evaluation of clinical heterogeneity between 
both forms of the disease. Journal of Medical Genetics, 32, 442–
445. https://doi.org/10.1136/jmg.32.6.442
Delmas, P., Nomura, H., Li, X., Lakkis, M., Luo, Y., Segal, Y., … Zhou, 
J. (2002). Constitutive activation of G-proteins by polycystin-1 is 
antagonized by polycystin-2. Journal of Biological Chemistry, 277, 
11276–11283. https://doi.org/10.1074/jbc.M1104 83200
Deltas, C. C. (2001). Mutations of the human polycystic kidney disease 
2 (PKD2) gene. Human Mutation, 18(1), 13–24.
den Dunnen, J. T., & Antonarakis, S. E. (2003). Mutation nomenclature.
Curr Protoc Hum Genet. Chapter 7,Unit 7.13.
Erbay, S. H., Oljeski, S. A., & Bhadelia, R. (2004). Rapid devel-
opment of optic glioma in a patient with hybrid phakomatosis: 
Neurofibromatosis type 1 and tuberous sclerosis. American Journal 
of Neuroradiology, 25, 36–38.
Ercolino, T., Lai, R., Giachè, V., Melchionda, S., Carella, M., Delitala, 
A., … Fanciulli, G. (2014). Patient affected by neurofibromatosis 
type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-
line mutations in both NF1 and RET genes. Gene, 536, 332–335. 
https://doi.org/10.1016/j.gene.2013.12.003
Flego, V., Radojcic Badovinac, A., Plese, V., Kapovic, M., Beg-Zec, 
Z., & Zaputovic, L. (2003). Malignancy risk in patient with neu-
rofibromatosis and autosomal dominant polycystic kidney disease. 
Croatian Medical Journal, 44(4), 485–488.
Gogusev, J., Murakami, I., Doussau, M., Telvi, L., Stojkoski, A., 
Lesavre, P., & Droz, D. (2003). Molecular cytogenetic aberrations 
in autosomal dominant polycystic kidney disease tissue. Journal 
of the American Society of Nephrology, 14, 359–366. https://doi.
org/10.1097/01.ASN.00000 46963.60910.63
Gorgel, A., Cetinkaya, D. D., Salgur, F., Demirpence, M., Yilmaz, H., 
Karaman, E. H., … Paker, I. (2014). Coexistence of gastrointesti-
nal stromal tumors (GISTs) and pheochromocytoma in three cases 
of neurofibromatosis type 1 (NF1) with a review of the literature. 
Internal Medicine, 53(16), 1783–1789. https://doi.org/10.2169/inter 
nalme dicine.53.2012
Harris, P. C. (2018). The time for next-generation molecular genetic di-
agnostics in nephrology is now! Kidney International, 94, 237–239.
Harris, P. C., & Rossetti, S. (2010). Determinants of renal disease vari-
ability in ADPKD. Advances in Chronic Kidney Disease, 17(2), 
131–139.
Hateboer, N., Buchalter, M., Davies, S. J., Lazarou, L. P., & Ravine, 
D. (2000). Co-occurrence of autosomal dominant polycystic kid-
ney disease and Marfan syndrome in a kindred. American Journal 
of Kidney Diseases, 35, 753–760. https://doi.org/10.1016/S0272 
-6386(00)70026 -6
Hegedus, B., Banerjee, D., Yeh, T. H., Rothermich, S., Perry, A., 
Rubin, J. B., … Gutmann, D. H. (2008). Preclinical cancer ther-
apy in a mouse model of neurofibromatosis-1 optic glioma. Cancer 
Research, 68, 1520–1528. https://doi.org/10.1158/0008-5472.
CAN-07-5916
Hirbe, A. C., & Gutmann, D. H. (2014). Neurofibromatosis type 1: A 
multidisciplinary approach to care. The Lancet Neurology, 13(8), 
834–843. https://doi.org/10.1016/S1474 -4422(14)70063 -8
Hitchcock, E., & Gibson, W. T. (2017). A review of the genetics of 
intracranial berry aneurysms and implications for genetic coun-
seling. Journal of Genetic Counseling, 26(1), 21–23. https://doi.
org/10.1007/s1089 7-016-0029-8
Irazabal, M. V., Rangel, L. J., Bergstralh, E. J., Osborn, S. L., Harmon, 
A. J., Sundsbak, J. L., … Torres, V. E. (2015). Imaging classification 
of autosomal dominant polycystic kidney disease: A simple model 
for selecting patients for clinical trials. Journal of the American 
Society of Nephrology, 26(1), 160–172. https://doi.org/10.1681/
ASN.20131 01138
12 of 13 |   PECES Et al.
Johannessen, C. M., Johnson, B. W., Williams, S. M., Chan, A. W., 
Reczek, E. E., Lynch, R. C., … Cichowski, K. (2008). TORC1 is 
essential for NF1-associated malignancies. Current Biology, 18, 
56–62. https://doi.org/10.1016/j.cub.2007.11.066
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, 
E., & Cichowski, K. (2005). The NF1 tumor suppressor critically 
regulates TSC2 and mTOR. Proceedings of the National Academy 
of Sciences of the United States of America, 102, 8573–8578. https://
doi.org/10.1073/pnas.05032 24102
Kebudi, R., Tuncer, S., Upadhyaya, M., Peksayar, G., Spurlock, G., & 
Yazici, H. (2008). A novel mutation in the NF1 gene in two siblings 
with neurofibromatosis type 1 and bilateral optic pathway glioma. 
Pediatric Blood & Cancer, 50, 713–715.
Kim, E., Arnould, T., Sellin, L., Benzing, T., Comella, N., Kocher, 
O., … Walz, G. (1999). Interaction between RGS7 and polycystin. 
Proceedings of the National Academy of Sciences of the United 
States of America, 96(11), 6371–6376. https://doi.org/10.1073/
pnas.96.11.6371
Koczkowska, M., Callens, T., Chen, Y., Gomes, A., Hicks, A. D., Sharp, 
A., … Babovic-Vuksanovic, D. (2020). Clinical spectrum of individ-
uals with pathogenic NF1 missense variants affecting p.Met1149, 
p.Arg1276, and p.Lys1423: Genotype-phenotype study in neurofi-
bromatosis type 1. Human Mutation, 41, 299–315.
Kurtelius, A., Kallionpää, R. A., Huttunen, J., Huttunen, T. J., Helin, K., 
Koivisto, T., … Lindgren, A. E. (2017). Neurofibromatosis type 1 
is not associated with subarachnoid haemorrhage. PLoS One, 12(6), 
e0178711. https://doi.org/10.1371/journ al.pone.0178711
Magistroni, R., He, N., Wang, K., Andrew, R., Johnson, A., Gabow, 
P., … Coto, E. (2003). Genotype-renal function correlation in type 
2 autosomal dominant polycystic kidney disease. Journal of the 
American Society of Nephrology, 14(5), 1164–1174. https://doi.
org/10.1097/01.ASN.00000 61774.90975.25
Martignoni, G., Bonetti, F., Pea, M., Tardanico, R., Brunelli, M., & 
Eble, J. N. (2002). Renal disease in adults with TSC2/PKD1 con-
tiguous gene syndrome. American Journal of Surgical Pathology, 
26, 198–205. https://doi.org/10.1097/00000 478-20020 2000-00006
Mautner, V. F., Asuagbor, F. A., Dombi, E., Fünsterer, C., Kluwe, L., 
Wenzel, R., … Friedman, J. M. (2008). Assessment of benign tumor 
burden by whole-body MRI in patients with neurofibromatosis 1. 
Neuro-Oncology, 10(4), 593–598. https://doi.org/10.1215/15228 
517-2008-011
Messiaen, L., Vogt, J., Bengesser, K., Fu, C., Mikhail, F., Serra, E., … 
Kehrer-Sawatzki, H. (2011). Mosaic type-1 NF1 microdeletions as 
a cause of both generalized and segmental neurofibromatosis type-1 
(NF1). Human Mutation, 32, 213–219. https://doi.org/10.1002/
humu.21418
Nemethova, M., Bolcekova, A., Ilencikova, D., Durovcikova, D., 
Hlinkova, K., Hlavata, A., … Zatkova, A. (2013). Thirty-nine novel 
neurofibromatosis 1 (NF1) gene mutations identified in Slovak pa-
tients. Annals of Human Genetics, 77(5), 364–379.
Niemczyk, S., Niemczyk, M., Dylewska, M., Gołębiowski, M., 
Niemczyk, L., & Gomółka, M. (2010). Multiple intercostal neuro-
fibromas in a patient with autosomal dominant polycystic kidney 
disease. Nephrology (Carlton), 15(8), 777–778.
NIH. (1988). National Institutes of Health Consensus Development 
Conference Statement: Neurofibromatosis. Bethesda, Md, USA, 
July 13–15, 1987. Neurofibromatosis, 1(3), 172–178.
Oktenli, C., Gul, D., Deveci, M. S., Saglam, M., Upadhyaya, M., & Eng, 
C. (2004). Unusual features in a patient with neurofibromatosis type 
1: Multiple subcutaneous lipomas, a juvenile polyp in ascending 
colon, congenital intrahepatic portosystemic venous shunt, and 
horseshoe kidney. American Journal of Medical Genetics, 127A(3), 
298–301.
Park, V. M., & Pivnick, E. K. (1998). Neurofibromatosis type 1 (NF1): 
A protein truncation assay yielding identification of mutations in 
73% of patients. Journal of Medical Genetics, 35, 813–820.
Pasmant, E., Sabbagh, A., Spurlock, G., Laurendeau, I., Grillo, E., 
… Lacombe, D. (2010). NF1 microdeletions in neurofibromato-
sis type 1: From genotype to phenotype. Human Mutation, 31(6), 
E1506–E1518.
Pei, Y., Obaji, J., Dupuis, A., Paterson, A. D., Magistroni, R., Dicks, 
E., … Ravine, D. (2009). Unified criteria for ultrasonographic diag-
nosis of ADPKD. Journal of the American Society of Nephrology, 
20(1), 205–212.
Pemov, A., Li, H., Patidar, R., Hansen, N. F., Sindiri, S., Hartley, S. 
W., …Stewart, D. R. (2017). The primacy of NF1 loss as the driver 
of tumorigenesis in neurofibromatosis type 1-associated plexi-
form neurofibromas. Oncogene, 36(22), 3168–3177. https://doi.
org/10.1038/onc.2016.464
Plotkin, S. R., Bredella, M. A., Cai, W., Kassarjian, A., Harris, G. J., 
Esparza, S., … Mautner, V. F. (2012). Quantitative assessment 
of whole-body tumor burden in adult patients with neurofibro-
matosis. PLoS One, 7(4), e35711. https://doi.org/10.1371/journ 
al.pone.0035711
Prada, C. E., Zarate, Y. A., Hagenbuch, S., Lovell, A., Schorry, E. K., & 
Hopkin, R. J. (2011). Lethal presentation of neurofibromatosis and 
Noonan syndrome. American Journal of Medical Genetics Part A, 
155A, 1360–1366. https://doi.org/10.1002/ajmg.a.33996
Rasmussen, S. A., Yang, Q., & Friedman, J. M. (2001). Mortality in 
neurofibromatosis 1: An analysis using U.S. death certificates. 
American Journal of Human Genetics, 68, 1110–1118.
Robinson, C., Hiemstra, T. F., Spencer, D., Waller, S., Daboo, L., Frankl, 
F. E. K., & Sandford, R. N. (2012). Clinical utility of PKD2 muta-
tion testing in a polycystic kidney disease cohort attending a spe-
cialist nephrology out-patient clinic. BMC Nephrology, 13, 79–79. 
https://doi.org/10.1186/1471-2369-13-79
Rossetti, S., Burton, S., Strmecki, L., Pond, G. R., San Millán, J. L., 
Zerres, K., … Winearls, C. G. (2002). The position of the polycystic 
kidney disease 1 (PKD1) gene mutation correlates with the severity 
of renal disease. Journal of the American Society of Nephrology, 
13(5), 1230–1237.
Sampson, J. R., Maheshwar, M. M., Aspinwall, R., Thompson, P., 
Cheadle, J. P., Ravine, D., … Harris, P. C. (1997). Renal cystic dis-
ease in tuberous sclerosis: Role of the polycystic kidney disease 1 
gene. The American Journal of Human Genetics, 61(4), 843–851. 
https://doi.org/10.1086/514888
Shillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, 
R., Brown, N., … Weimbs, T. (2006). The mTOR pathway is regu-
lated by polycystin-1, and its inhibition reverses renal cystogenesis 
in polycystic kidney disease. Proceedings of the National Academy 
of Sciences of the United States of America, 103, 5466–5471. https://
doi.org/10.1073/pnas.05096 94103
Siegelman, S. S., Zavod, R., & Hecht, H. (1971). Neurofibromatosis, 
polycystic kidneys, and hypernephroma. New York State Journal of 
Medicine, 71, 2431–3243.
Stewart, D. R., Korf, B. R., Nathanson, K. L., Stevenson, D. A., & Yohay, 
K. (2018). Care of adults with neurofibromatosis type 1: A clinical 
practice resource of the American College of Medical Genetics and 
Genomics (ACMG). Genetics in Medicine, 20, 671–682. https://doi.
org/10.1038/gim.2018.28
   | 13 of 13PECES Et al.
Sylvester, C. L., Drohan, L. A., & Sergott, R. (2006). Optic nerve gli-
omas, chiasmal gliomas and neurofibromatosis type 1. Current 
Opinion in Ophthalmology, 17, 7–11. https://doi.org/10.1097/01.
icu.00001 93070.32369.37
Syro, L. V., Sundsbak, J. L., Scheithauer, B. W., Toledo, R. A., Camargo, 
M., & Heyer, C. M. (2012). Somatotroph pituitary adenoma with 
acromegaly and autosomal dominant polycystic kidney disease: 
SSTR5 polymorphism and PKD1 mutation. Pituitary, 15, 342–349.
Thiel, C., Wilken, M., Zenker, M., Sticht, H., Fahsold, R., Gusek-
Schneider, G. C., & Rauch, A. (2009). Independent NF1 and 
PTPN11 mutations in a family with neurofibromatosis-Noonan 
syndrome. American Journal of Medical Genetics Part A, 149A, 
1263–1267.
Tonsgard, J. H., Kwak, S. M., Short, M. P., & Dachman, A. H. (1998). 
CT imaging in adults with neurofibromatosis-1: Frequent asymp-
tomatic plexiform lesions. Neurology, 50(6), 1755–1760.
Torres, V. E., Harris, P. C., & Pirson, Y. (2007). Autosomal dominant 
polycystic kidney disease. Lancet, 369(9569), 1287–1301. https://
doi.org/10.1016/S0140 -6736(07)60601 -1
Valero, M. C., Martín, Y., Hernández-Imaz, E., Marina Hernández, A., 
Meleán, G., Valero, A. M., … Hernández-Chico, C. (2011). A highly 
sensitive genetic protocol to detect NF1 mutations. The Journal of 
Molecular Diagnostics, 13, 113–122.
Valero, M. C., Velasco, E., Moreno, F., & Hernández-Chico, C. 
(1994). Characterization of four mutations in the neurofibromato-
sis type 1 gene by denaturing gradient gel electrophoresis (DGGE). 
Human Molecular Genetics, 3, 639–641. https://doi.org/10.1093/
hmg/3.4.639
Varmac, S. C., Talwar, K. K., Kushik, S. P., & Sharma, B. K. (1982). 
Association of von Recklinghausen's neurofibromatosis with adult 
polycystic disease of kidneys and liver. Postgraduate Medical 
Journal, 58, 117–118.
Wahl, P. R., Al, S., Le Hir, M., Molle, K. D., Hall, M. N., & Wthrich, R. 
P. (2006). Inhibition of mTOR with sirolimus slows disease progres-
sion in Han: SPRD rats with autosomal dominant polycystic kid-
ney disease (ADPKD). Nephrology, Dialysis, Transplantation, 21, 
598–604. https://doi.org/10.1093/ndt/gfi181
Walther, M. M., Herring, J., Enquist, E., Keiser, H. R., & Linehan, W. 
M. (1999). Von Recklinghausen´s disease and pheochromocytomas. 
Journal of Urology, 162, 1582–1586. https://doi.org/10.1016/S0022 
-5347(05)68171 -2
Ward, B. A., & Gutmann, D. H. (2005). Neurofibromatosis 1: From lab 
bench to clinic. Pediatric Neurology, 32(4), 221–228. https://doi.
org/10.1016/j.pedia trneu rol.2004.11.002
Wen, P. Y., & Kesari, S. (2008). Malignant gliomas in adults. 
New England Journal of Medicine, 359, 492–507. https://doi.
org/10.1056/NEJMr a0708126
Wheeler, P. G., & Sadeghi-Nejad, A. (2005). Simultaneous occurrence 
of neurofibromatosis type 1 and tuberous sclerosis in a young girl. 
American Journal of Medical Genetics, 133A, 78–81. https://doi.
org/10.1002/ajmg.a.30530
Willey, C. J., Blais, J. D., Hall, A. K., Krasa, H. B., Makin, A. J., & 
Czerwiec, F. S. (2017). Prevalence of autosomal dominant poly-
cystic kidney disease in the European Union. Nephrology, Dialysis, 
Transplantation, 32(8), 1356–1363.
Yap, P., Super, L., Qin, J., Burgess, T., Prodanovic, Z., Edwards, C., 
… Tan, T. Y. (2017). Congenital retroperitoneal teratoma in neu-
rofibromatosis Type 1. Pediatric Blood & Cancer, 63(4), 706–708.
Zhang, S., Mei, C., Zhang, D., Dai, B., Tang, B., Sun, T., … Song, J. I. 
(2005). Mutation analysis of autosomal dominant polycystic kidney 
disease genes in Han Chinese. Nephron Experimental Nephrology, 
100, e63–e76. https://doi.org/10.1159/00008 4572
How to cite this article: Peces R, Mena R, Martín Y, 
et al. Co-occurrence of neurofibromatosis type 1 and 
optic nerve gliomas with autosomal dominant 
polycystic kidney disease type 2. Mol Genet Genomic 
Med. 2020;8:e1321. https://doi.org/10.1002/
mgg3.1321
